Ionis rally raises questions over valuation after strong run

Shares in Ionis Pharmaceuticals have surged more than 150 per cent over the past year, prompting investors to reassess whether further upside remains or if much of the growth story is already priced in.

The stock, recently trading around $74, has shown mixed momentum in recent weeks, slipping modestly over the past seven days while posting gains over the past month. The sharp rise over the past year reflects renewed investor interest in biotech groups with specialised pipelines, even as short-term volatility suggests some caution is emerging.

Valuation metrics present a divided picture. A discounted cash flow analysis, based on projections that Ionis will transition from negative free cash flow to substantial profitability over the coming decade, points to a theoretical value well above the current share price. On that basis, the stock could appear significantly undervalued, assuming the company delivers on long-term growth expectations.

However, other measures indicate a more demanding valuation. Ionis trades at a price-to-sales ratio of roughly 13 times, above both the broader biotech sector and many peers, suggesting investors are already assigning a premium to its revenue prospects and pipeline potential.

The divergence reflects differing assumptions about the company’s trajectory. A more optimistic view hinges on Ionis expanding beyond rare disease treatments into larger markets, supported by partnerships with groups such as Biogen, AstraZeneca and Roche. This scenario would see accelerating revenues and a shift towards sustained profitability.

A more cautious outlook points to pricing pressures as the company targets broader patient populations, alongside continued high research and commercial spending. Under this view, margins may remain constrained, limiting the scope for further share price gains.

For investors, the question is less about recent performance than whether Ionis can convert its pipeline into durable earnings growth. After a year of outsized returns, the answer will depend on how much of that potential the market has already priced in.